1:31 PM · 13 May 2020

Gilead Sciences signed a deal for remdesivir.

Gilead Sciences (GILD.US)   announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.


Gilead Sciences (GILD.US)  shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5

16 June 2026, 2:56 PM

US OPEN: SpaceX pushes Amazon off the TOP 5 podium. Wall Street awaits Warsh's debut

16 June 2026, 1:11 PM

SpaceX Acquires Cursor for $60 Billion. Why Musk Needed Cursor So Badly

16 June 2026, 11:33 AM

European stocks on the rise again 🔼 EU50 near record high

16 June 2026, 10:13 AM

SpaceX shares continue to soar 🔼 The stock is up nearly 30% since its record-breaking IPO

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits